Pre-market hot trades in US stocks: Texxon pre-market down 7.25%; UnitedHealth pre-market down 4.79%

Pre-market Hot Trades in US Stocks Texxon, down 7.25% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. UnitedHealth down 4.79% in pre-market. Based on recent key news: On May 16, Berkshire Hathaway completely divested its holdings in UnitedHealth, putting pressure on the stock price. According to SEC filings, Berkshire Hathaway has sold all its shares in UnitedHealth Group, affecting market confidence in the stock. On May 16, UnitedHealth disclosed AI-related risks in its annual report, increasing market uncertainty. The company warned that the use of AI could bring legal, regulatory, and business risks, impacting operations and financial performance. On May 17, analyst ratings were not included in the recommended list, affecting investor sentiment. MarketBeat noted that although UnitedHealth has a "Moderate Buy" rating, top analysts believe that five other stocks offer better investment value. The healthcare industry faces regulatory and technological risks. Top Gainers in Pre-market US Stocks Sunshine Biopharma, up 214.08% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. GeoVax Labs up 103.25% in pre-market. Based on recent key news: On May 14, GeoVax Labs announced through the SEC that it is shifting its strategic focus to the GEO-MVA project while continuing to develop Gedeptin as a long-term immunotherapy option. This strategic adjustment is viewed as a positive signal by the market, driving a significant increase in stock price. Source: EDGAR system On May 14, GeoVax Labs mentioned adjustments in capital and operational priorities in its announcement, leading the market to hold an optimistic view of its future development prospects, further stimulating the stock price increase. Source: SEC filings No other significant news recently. The biotechnology sector has been quite volatile lately and requires attention